Back to discover
Disease

Pain

Late-stage therapeutic developmentActively researchedRising momentum
32
Publications
24
Clinical trials
9
Related conditions
2
Related proteins
2024
Latest publication
Latest activity
beta

Recent clinical, regulatory, research and industry developments relating to this disease.

Pathology of pain and its implications for therapeutic interventions.

Research2024-06-08Signal transduction and targeted therapy

Influence of Inflammatory Pain and Dopamine on Synaptic Transmission in the Mouse ACC.

Research2023-07-05International journal of molecular sciences

Approval: Dzuveo (EMA)

Regulatory2018-06-25EMA

Approval: PecFent (EMA)

Regulatory2010-08-31EMA

Approval: Instanyl (EMA)

Regulatory2009-07-20EMA

Approval: Effentora (EMA)

Regulatory2008-04-04EMA

What's happening now

An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.

Clinical Milestones17View all 17
+9 more in the activity timeline below
Industry & Market12View all 12
Activity timeline29

Clinical trials

18 sponsors · 5 new · 6 completed in the last 12 months (net +2)

The current development programme across all trial phases.

Clinical programme
24
All trials
6
Active
18
Late-stage
6
Completed
Late-stage studies
Recently completed

Evidence coverage

8 treatments

How much of this condition's readable clinical evidence the confidence engine has incorporated, across its most-studied treatments. This measures coverage of the evidence base — not whether any treatment works.

Limited evidence coverage
35% · 56/162 eligible items incorporated

Largest gap: no meaningful change (56, trial-readability).

Research activity

32 papers

Key research shaping understanding of this disease, combining the latest publications with the most influential evidence.

Publications over time
20042024
Most influential

Depression and pain comorbidity: a literature review.

Archives of internal medicine · 2003 · 2,335 cites

Nociceptors: the sensors of the pain pathway.

The Journal of clinical investigation · 2010 · 812 cites

Central modulation of pain.

The Journal of clinical investigation · 2010 · 781 cites

Prevalence of depression in patients with cancer.

Journal of the National Cancer Institute. Monographs · 2004 · 723 cites
Recent publications
Major themes8
  • Neoplasms2
  • Pain2
  • Adaptive Immunity1
  • Affect1
  • Angioplasty, Balloon, Coronary1
  • Bone Neoplasms1
  • Brain-Derived Neurotrophic Factor1
  • Computer Simulation1
Leading journals6
  • The Journal of neuroscience : the official journal of the Society for Neuroscience4
  • International journal of molecular sciences3
  • The Journal of clinical investigation3
  • Frontiers in immunology2
  • Journal of neuroinflammation2
  • Advances in therapy1
Leading researchers8
  • Liu F2
  • Aiyegbusi OL1
  • Andersson DA1
  • Backus LR1
  • Baharpoor A1
  • Bair MJ1
  • Bao T1
  • Barton D1
Affiliations (unnormalised)6
  • College of Medicine3
  • School of Pharmacy2
  • University Hospitals Birmingham NHS Foundation Trust2
  • Aix-Marseille Université1
  • American Society of Clinical Oncology1
  • Birmingham Clinical Trials Unit1

Disease biology

2 matches

Key proteins & gene products studied in this disease. Number shows shared papers.

Related conditions

9 matches

Diseases frequently studied alongside this one. Number shows shared papers.

Disease profile

A grounded synthesis of the condition — overview, causes, mechanism, risk factors and current standard of care.

Overview

Pain is an unpleasant sensation triggered by noxious stimuli detected by nerve endings of nociceptive neurons. It is a sensory experience that can vary substantially between individuals and can be influenced by both peripheral input and central modulation.

Causes

Pain is caused by activation of nociceptors by potentially damaging stimuli, including extremes of temperature and pressure and injury-related chemicals. The literature also supports pain arising or being amplified in association with opioid exposure, depression, and long COVID, but these are described as associated contexts rather than sole causes.

Pathophysiology

Pain begins when specialized peripheral sensory neurons transduce noxious stimuli into electrical signals that are relayed to higher brain centers. The literature also describes modulation through nociception, neuronal plasticity, signal transduction, synaptic transmission, excitatory postsynaptic potentials, and top-down central circuits, with shared biological pathways and neurotransmitters such as serotonin and inflammatory mediators including cytokines and tumor necrosis factor-alpha.

Risk factors

Factors associated with greater pain burden include depression, moderate to severe pain, impaired function, and refractory symptoms. Emotional state, anxiety, attention and distraction, past experiences, and memories can also enhance the pain experience, and opioid exposure is associated with opioid-induced hyperalgesia.

Current standard of care

The grounding supports drug therapy as a general management modality, but does not specify a particular standard regimen. The literature also points to broader management of pain comorbidity and modulation, including approaches informed by neurotransmitter and inflammatory pathways, but not to a specific drug class as universal standard of care.

AI-generated summary grounded in MeSH and 6 peer-reviewed sources. Informational only — not medical advice. Generated 2026-07-07.

Reference

Authoritative identity, definition & identifiers.

Defined in MeSH

An unpleasant sensation induced by noxious stimuli which are detected by NERVE ENDINGS of NOCICEPTIVE NEURONS.

Identifiers
References & data sources
  • Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
  • Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
  • Research activity — Europe PMC (EMBL-EBI) + OpenAlex-derived paper links
  • Related entities are derived from literature co-mention (studied together) — associative, not causal.